Immunocore (NASDAQ:IMCR) Stock Price Down 4.4% – Time to Sell?

Posted by Francis Steltz on Sep 11th, 2026

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR – Get Free Report) fell 4.4% during trading on Friday . The company traded as low as $33.10 and last traded at $32.9550. 6,745 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 454,839 shares. The stock had previously closed at $34.47.

Analysts Set New Price Targets

IMCR has been the topic of a number of recent analyst reports. TD Cowen raised Immunocore to a “strong-buy” rating in a research note on Monday, August 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a research report on Monday, July 13th. Mizuho upped their price objective on shares of Immunocore from $34.00 to $35.00 and gave the company a “neutral” rating in a research note on Monday, August 3rd. Morgan Stanley set a $43.00 price objective on shares of Immunocore in a research report on Friday, August 7th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $56.38.

Check Out Our Latest Stock Report on Immunocore

Immunocore Stock Performance

The company has a quick ratio of 4.44, a current ratio of 4.47 and a debt-to-equity ratio of 0.94. The company has a 50 day simple moving average of $34.76 and a 200-day simple moving average of $31.81. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of -89.24 and a beta of 0.74.

Immunocore (NASDAQ:IMCR – Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%. As a group, equities research analysts expect that Immunocore Holdings PLC Sponsored ADR will post 0.06 EPS for the current fiscal year.

Institutional Investors Weigh In On Immunocore

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Leonteq Securities AG bought a new position in shares of Immunocore during the 4th quarter worth about $30,000. Harbour Investments Inc. increased its position in Immunocore by 60.2% in the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after buying an additional 388 shares in the last quarter. Rockefeller Capital Management L.P. bought a new stake in Immunocore in the 4th quarter valued at about $47,000. Arax Advisory Partners raised its stake in Immunocore by 302.9% during the 4th quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock worth $48,000 after buying an additional 1,042 shares during the period. Finally, GAMMA Investing LLC boosted its holdings in Immunocore by 202.8% in the second quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock worth $61,000 after acquiring an additional 1,286 shares in the last quarter. 84.50% of the stock is owned by institutional investors.

Immunocore Company Profile

(Get Free Report)

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.